Forte Biosciences IncNASDAQ:FBRX
- LAST PRICE4.3700
- TODAY'S CHANGE (%)0.1900 (4.5455%)
- Bid / Lots4.0000/ 2
- Ask / Lots4.9500/ 1
- Open / Previous Close4.1800 / 4.1800
- Day Range
- 52 Week Range
- Volume19,681
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 09:51 ET | 3200 | 4.29 |
| 09:53 ET | 2901 | 4.25 |
| 10:11 ET | 100 | 4.27 |
| 10:33 ET | 100 | 4.27 |
| 10:42 ET | 500 | 4.3752 |
| 11:05 ET | 153 | 4.38 |
| 11:07 ET | 100 | 4.38 |
| 11:09 ET | 100 | 4.38 |
| 11:12 ET | 100 | 4.38 |
| 11:27 ET | 300 | 4.2264 |
| 11:30 ET | 200 | 4.3795 |
| 11:54 ET | 1400 | 4.31 |
| 11:59 ET | 200 | 4.2769 |
| 12:01 ET | 3566 | 4.2857 |
| 12:03 ET | 2050 | 4.25 |
| 12:06 ET | 2701 | 4.3 |
| 12:12 ET | 100 | 4.33 |
| 12:17 ET | 100 | 4.325 |
| 01:31 ET | 100 | 4.33 |
| 03:57 ET | 100 | 4.37 |
| 04:00 ET | 307 | 4.37 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 6.1M | -0.2x | --- |
Enzon Pharmaceuticals Inc | 6.1M | 18.6x | -60.21% |
Purple Biotech Ltd | 6.1M | 0.0x | --- |
Windtree Therapeutics Inc | 6.3M | -0.9x | --- |
CeCors Inc | 6.3M | --- | --- |
Mosaic Immunoengineering Inc | 5.9M | -4.9x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Paul Wagner
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
- Independent Director
- Barbara Finck
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.02 |
EPS | $-22.03 |
Book Value | $24.30 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
